Your search for chronic kidney disease returned 597 results

Latest findings are from a post hoc meta-analysis of pooled data from the DAPA-HF and DELIVER trials.

Guidelines support the use of RAASi at the maximum tolerated dose in patients with CKD and heart failure.

Despite a warning from the FDA Adverse Event Reporting System, studies have found that SGLT2 inhibitor use is not associated with an increased risk of AKI.

Up to 40% of patients with IgAN progress to end-stage kidney disease, investigators noted.

Patients receiving significant amount of immunosuppression prior to kidney transplantation should be counseled on these malignancy risks, according to investigators.

If renin-angiotensin system inhibitors are indicated in patients with advanced CKD, they should not be stopped just because of low eGFR, investigators concluded.

Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor.

Danish investigators compared direct oral anticoagulants with vitamin K antagonists in 33,670 patients with atrial fibrillation.

Patients with advanced CKD have not been well-represented in trials evaluating intensive blood pressure control.

Tecarfarin is a novel oral vitamin K antagonist with a similar mechanism of action to warfarin, though it is metabolized differently.